A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

被引：0
作者：
Rischin, D. [1 ,2 ]
Fury, M. G. [3 ]
Lowy, I. [3 ]
Stankevich, E. [3 ]
Li, S. [3 ]
Han, H. [3 ]
Porceddu, S. V. [4 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Regeneron Pharmaceut Inc, Clin Sci, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Univ Queensland, Sch Med, Princess Alexandra Hosp, Dept Radiat Oncol, Herston, Qld, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1372TiP
引用
收藏
页码：560 / 560
页数：1
相关论文
共 50 条
  • [41] Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: A systematic review of available outcome data
    Iambusaria-Pahlajani, A.
    Smith, N.
    Klein, R.
    Miller, C. J.
    Quon, H.
    Schmults, C. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 : S81 - S81
  • [42] High Risk Head and Neck Cutaneous Squamous Cell Carcinoma Treated With Mohs Surgery or Mohs Surgery and Adjuvant Radiation Therapy
    Anker, C. J.
    Sajisevi, M.
    Cintolo-Gonzalez, J. A.
    Bax, D. P.
    Chen, D. L.
    Goldman, G. D.
    Holmes, T. E.
    Leonard, K. W.
    Rehman, H. T.
    Self, Q. R.
    Weinberger, C. H.
    Bui, M. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E313 - E313
  • [43] Re: Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial
    Pouliot, Frederic
    Pantuck, Allan J.
    EUROPEAN UROLOGY, 2009, 55 (06) : 1482 - 1484
  • [44] Inferior Outcomes in Immunosuppressed Patients With High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Surgery and Radiation Therapy
    Manyam, B.
    Saxton, J. P.
    Reddy, C. A.
    Burkey, B. B.
    Scharpf, J.
    Zhang, A. Y.
    Alam, D. S.
    Fritz, M. A.
    Vidimos, A. T.
    Koyfman, S. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 476 - 476
  • [45] Inferior Outcomes in Immunosuppressed Patients With High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Surgery and Radiation Therapy
    Manyam, B.
    Saxton, J. P.
    Reddy, C. A.
    Burkey, B. B.
    Scharpf, J.
    Zhang, A. Y.
    Gastman, B.
    Fritz, M. A.
    Vidimos, A. T.
    Koyfman, S. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S764 - S765
  • [46] Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy
    Manyam, Bindu V.
    Gastman, Brian
    Zhang, Alexandra Y.
    Reddy, Chandana A.
    Burkey, Brian B.
    Scharpf, Joseph
    Alam, Daniel S.
    Fritz, Michael A.
    Vidimos, Allison T.
    Koyfman, Shlomo A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 221 - 227
  • [47] A Phase II Multicenter Double-Blind Placebo-Controlled Study of Ethyl Pyruvate in High-Risk Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
    Bennett-Guerrero, Elliott
    Swaminathan, Madhav
    Grigore, Alina M.
    Roach, Gary W.
    Aberle, Laura G.
    Johnston, Jeffrey M.
    Fink, Mitchell P.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2009, 23 (03) : 324 - 329
  • [48] Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
    Fassnacht, Martin
    Berruti, Alfredo
    Baudin, Eric
    Demeure, Michael J.
    Gilbert, Jill
    Haak, Harm
    Kroiss, Matthias
    Quinn, David I.
    Hesseltine, Elizabeth
    Ronchi, Cristina L.
    Terzolo, Massimo
    Choueiri, Toni K.
    Poondru, Srinivasu
    Fleege, Tanya
    Rorig, Ramona
    Chen, Jihong
    Stephens, Andrew W.
    Worden, Francis
    Hammer, Gary D.
    LANCET ONCOLOGY, 2015, 16 (04) : 426 - 435
  • [49] Health-related Quality of Life (HRQoL) in Patients with advanced cutaneous Squamous Cell Carcinoma (CSCC) treated with Cemiplimab: Post hoc exploratory Analysis of a clinical Phase-2-Study
    Migden, M. R.
    Rischin, D.
    Sasane, M.
    Mastey, V.
    Pavlick, A.
    Schmults, C. D.
    Chen, Z.
    Guminski, A.
    Hauschild, A.
    Bury, D.
    Chang, A. L. S.
    Rabinowits, G.
    Ibrahim, S.
    Lowy, I.
    Fury, M. G.
    Li, S.
    Chen, C. I.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 22 - 22
  • [50] Neoadjuvant cemiplimab in patients (pts) with stage II-IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study
    Gross, N.
    Miller, D. M.
    Khushanlani, N.
    Divi, V.
    Ruiz, E. S.
    Lipson, E. J.
    Meier, F.
    Su, Y. B.
    Swiecicki, P. L.
    Atlas, J. L.
    Geiger, J. L.
    Hauschild, A.
    Choe, J. H.
    Hughes, B. G. M.
    Yoo, S-Y.
    Fenech, K.
    Mathias, M. D.
    Han, H.
    Fury, M. G.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S904 - S905
12345